Moleculin Biotech, INC. 8-K Filing

Filing Documents

• mbrx20251205_8k.htm (8-K) — 26KB
• ex_896158.htm (EX-99.1) — 18KB
• m01.jpg (GRAPHIC) — 8KB
• 0001437749-25-037084.txt ( ) — 198KB
• mbrx-20251208.xsd (EX-101.SCH) — 3KB
• mbrx-20251208_def.xml (EX-101.DEF) — 11KB
• mbrx-20251208_lab.xml (EX-101.LAB) — 15KB
• mbrx-20251208_pre.xml (EX-101.PRE) — 11KB
• mbrx20251205_8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure On December 8, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced it has entered into research and material transfer agreement with CIC biomaGUNE, a non-profit research organization created to promote scientific research and technological innovation at the highest levels in the Basque Country, Spain, for investigator-initiated preclinical research evaluating Annamycin for the treatment of glioblastoma multiforme (GBM), a form of brain cancer. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 8, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: December 8, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster

View Full Filing

View this 8-K filing on SEC EDGAR